What is Formulary? Definition, Formula, and Benchmark

A formulary is a health plan's published list of covered prescription drugs along with applicable utilization management rules and cost-sharing tiers. Formularies serve as the operational framework for what medications are covered, what patients pay, and what prescribing workflow applies. Health plans, PBMs, and public programs (Medicare Part D, Medicaid) all maintain formularies, though with different governance and coverage requirements.

Formularies are managed by Pharmacy and Therapeutics (P&T) committees — typically multidisciplinary groups of physicians, pharmacists, and clinical experts who review drug evidence, assess therapeutic alternatives, and make coverage recommendations. P&T committee decisions consider clinical efficacy, safety profiles, therapeutic class positioning, FDA-approved indications, and cost (including rebate dynamics). Committee meetings occur quarterly or more frequently; formulary updates are published with effective dates, and patients typically receive 60-day advance notice of formulary changes that affect their current prescriptions.

Tier structures organize formulary drugs by cost-sharing. Common five-tier structures include: Tier 1 (preferred generics, lowest copay $5–$10); Tier 2 (preferred brand-name, moderate copay $30–$50); Tier 3 (non-preferred brand, higher copay $60–$100); Tier 4 (preferred specialty, coinsurance 20–30%); Tier 5 (non-preferred specialty, coinsurance 33–50%). The tier determines the member's out-of-pocket cost at the pharmacy counter.

Utilization management rules are attached to specific formulary entries. Prior authorization (PA): prescriber must submit clinical justification before the drug is approved. Step therapy (ST): cheaper first-line alternatives must fail or be contraindicated before the requested drug is covered. Quantity limits (QL): pharmacy claim rejects beyond specified day-supply or fill frequency. Age edits, gender edits, and diagnosis-requirement edits add further granular control. These UM rules collectively manage drug spending and safety.

Medicare Part D formularies are subject to specific CMS requirements. Covered drug classes include all six "protected classes" (immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, antineoplastics) where plans must include substantially all drugs in the class. Plans must cover at least two drugs in most therapeutic categories and subcategories per USP Medicare Model Guidelines. Tiered cost-sharing is allowed but with coverage protection for critical drugs.

For providers, formulary awareness at prescribing time is critical to patient adherence and clinical outcomes. EHR integrations with eligibility services (E-prescribing enhancements, RxPath, real-time pharmacy benefit check services) surface formulary status, cost, PA requirements, and alternatives during prescribing. Ignoring formulary creates patient cost sticker-shock at pharmacy, prescription abandonment, and downstream clinical consequences.

Formulary exceptions and appeals processes provide patient escape routes. If a patient needs a non-formulary drug based on clinical necessity, the prescriber can request formulary exception — demonstrating that formulary alternatives are inadequate, contraindicated, or intolerable. Approved exceptions typically cover the drug at the highest tier cost-sharing. Medicare Part D has specific exception processes; commercial plans and state Medicaid programs have similar but plan-specific procedures. Appeals through internal and external review are available when exceptions are denied.

Specialty drug formulary management has grown increasingly complex. Tier 4 and Tier 5 specialty drugs often have 20–40% coinsurance with no monthly cap, producing patient out-of-pocket costs of thousands of dollars per month. Payer specialty pharmacy channeling, manufacturer patient assistance programs, copay assistance foundations, and innovative payment models (value-based contracts, outcomes-based arrangements) increasingly shape specialty drug access.

Formulary transparency requirements are evolving. Federal and state legislation around PBM transparency, Medicare Price Negotiation implementation (IRA 2022), and consumer-facing cost transparency tools continue to reshape formulary disclosure practices.